Regeneron Pharmaceuticals (NASDAQ:REGN) Sets New 12-Month Low After Analyst Downgrade

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares reached a new 52-week low on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $1,100.00 to $1,000.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Regeneron Pharmaceuticals traded as low as $618.51 and last traded at $630.08, with a volume of 111538 shares. The stock had previously closed at $637.36.

A number of other analysts have also recently issued reports on REGN. Robert W. Baird reduced their target price on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research note on Wednesday, February 5th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $762.00 to $834.00 in a research note on Wednesday, February 5th. Truist Financial lowered their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Bernstein Bank cut their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Finally, Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $966.88.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in REGN. Capital International Investors grew its stake in shares of Regeneron Pharmaceuticals by 41.6% in the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock valued at $3,373,859,000 after purchasing an additional 1,390,534 shares during the period. Norges Bank bought a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $802,036,000. Price T Rowe Associates Inc. MD raised its stake in Regeneron Pharmaceuticals by 63.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock worth $1,485,527,000 after acquiring an additional 810,144 shares in the last quarter. Amundi raised its stake in Regeneron Pharmaceuticals by 45.8% during the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock worth $1,138,074,000 after acquiring an additional 487,489 shares in the last quarter. Finally, Loomis Sayles & Co. L P lifted its holdings in shares of Regeneron Pharmaceuticals by 33.4% during the fourth quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company’s stock valued at $1,122,168,000 after acquiring an additional 393,997 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

The company has a market cap of $67.45 billion, a price-to-earnings ratio of 16.12, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company’s 50 day moving average price is $681.52 and its 200 day moving average price is $788.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the prior year, the firm earned $11.86 earnings per share. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were issued a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.57%. Regeneron Pharmaceuticals’s dividend payout ratio is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.